MedTrace Logo

HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin

NCT01718301 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2025-08-24

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the safety and efficacy of a Response Guided Therapy of boceprevir 800 mg dosed three times a day (TID) orally (PO) in combination with Peginterferon (either alpha 2b or alpha 2a) and Ribavirin in HIV/HCV genotype 1 infected patients that failed to previous HCV therapy.

Conditions

  • Hepatitis C
  • HIV Infections
  • COINFECTION

Interventions

DRUG

boceprevir

DRUG

Ribavirin

DRUG

Peginterferon alfa-2a

DRUG

Peginterferon alfa-2b

Sponsors & Collaborators

  • Anna Cruceta

    lead OTHER

Principal Investigators

  • Josep Mallolas, MD · Hospital Clínic i Provincial de Barcelona

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-10
Primary Completion
2015-03-20
Completion
2015-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01718301 on ClinicalTrials.gov